Actively Recruiting
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Led by AHS Cancer Control Alberta · Updated on 2025-06-12
31
Participants Needed
1
Research Sites
176 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.
CONDITIONS
Official Title
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Minimum 18 years of age
- Biopsy proven, newly diagnosed, untreated small cell lung cancer
- Completed standard staging including CT chest/abdomen/pelvis, bone scan and/or PET-CT, CT head or MRI brain, or chest X-ray
- Eligible for platinum doublet chemotherapy
- Eligible for thoracic radiotherapy including ipsilateral supraclavicular lymph node disease
- Able to provide written informed consent or have a legally authorized representative sign
- Willing and able to comply with study protocol and follow-up
- Performance status ECOG 0-2
- Pulmonary function tests with FEV-1 greater than 1.0L and DLCO greater than 50% predicted
- Radiation-targetable intrathoracic disease
You will not qualify if you...
- No intrathoracic disease suitable for radiation
- Thoracic disease extending beyond ipsilateral supraclavicular lymph nodes to extrathoracic sites
- Mixed histology disease
- Active serious infection requiring treatment
- Brain metastases not stable on dexamethasone
- Four or more sites of extrathoracic disease
- Previous central nervous system or thoracic radiotherapy
- Previous chemotherapy
- Not eligible for platinum doublet chemotherapy
- Life expectancy less than 3 months
- Prior thoracic surgery
- History of another primary cancer except basal cell carcinoma unless disease-free for 5 years
- Pregnant or breastfeeding
- In limited stage SCLC, not eligible for concurrent chemoradiotherapy
- In extensive stage SCLC, not eligible for concurrent chemoradiotherapy
- Allergy to CT contrast or kidney disease preventing IV contrast administration
- Intrathoracic disease not suitable for adaptive radiotherapy
- Participation in study development or conduct
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
Research Team
Y
Yee Don, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here